Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Lifecore Biomedical, Inc. Market Cap
The Lifecore Biomedical, Inc. (LFCR) share price is expected to increase by 9.89% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered LFCR. Price targets range from $6 at the low end to $10 at the high end. The current analyst consensus for LFCR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Lifecore Biomedical, Inc. has a total of 3 Wall St Analyst ratings. There are 1 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Lifecore Biomedical, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of LFCR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matthew Hewitt Craig-Hallum | Buy | $10 | Maintains | Nov 22, 2024 |
| Matthew Hewitt Craig-Hallum | Buy | $8 | Initiates | Sep 5, 2024 |
| Michael Petusky Barrington Research | Market Perform | Downgrade | Aug 28, 2024 | |
| Michael Petusky Barrington Research | Outperform | $10 | Maintains | Sep 1, 2023 |
| Jacob Johnson Stephens & Co. | Equal-Weight | $9 | Maintains | Sep 1, 2023 |
| Michael Petusky Barrington Research | Outperform | $11 | Maintains | Jun 2, 2023 |
| Michael Petusky Barrington Research | Outperform | $10 | Maintains | May 24, 2023 |
| Michael Petusky Barrington Research | Outperform | $8 | Maintains | Mar 21, 2023 |
| Jacob Johnson Stephens & Co. | Equal-Weight | $2 | Downgrade | Mar 20, 2023 |
| Michael Petusky Barrington Research | Outperform | $8 | Maintains | Mar 20, 2023 |
| Jacob Johnson Stephens & Co. | Overweight | $11 | Reiterates | Mar 17, 2023 |
UBS | Neutral | Maintains | Dec 9, 2022 | |
Goldman Sachs | Buy | Maintains | Dec 9, 2022 | |
Baird | Outperform | Maintains | Dec 9, 2022 | |
Morgan Stanley | Overweight | Maintains | Dec 9, 2022 | |
Piper Sandler | Overweight | Maintains | Dec 9, 2022 | |
Wells Fargo | Equal-Weight | Maintains | Dec 9, 2022 | |
Raymond James | Strong Buy | Maintains | Dec 6, 2022 | |
Citigroup | Neutral | Maintains | Dec 6, 2022 | |
Cowen & Co. | Outperform | Maintains | Dec 5, 2022 |
When did it IPO
1996
Staff Count
524
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Paul Josephs
Market Cap
$269.2M
In 2023, LFCR generated $103.3M in revenue, which was a decrease of -7.19% from the previous year. This can be seen as a signal that LFCR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sun, 01 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Lifecore is expanding production capacity to capture growth in the CDMO market and GLP-1 opportunities, expecting revenue and EBITDA improvements in H2 FY25 despite a tough Q1.
Why It Matters - Lifecore's expansion and focus on GLP-1 opportunities signal strong revenue growth potential, improved profitability, and increased market share in a growing CDMO sector, appealing to investors.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company has extended its term by three years, simplified its financial structure, and reduced interest rates, enhancing its balance sheet and financial stability.
Why It Matters - A three-year term extension and lower interest rates improve cash flow and reduce debt burden, enhancing financial stability and potentially increasing shareholder value.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Lifecore Biomedical (NASDAQ: LFCR) hosted a virtual investor day discussing growth strategy. A replay is available on their investor website.
Why It Matters - Lifecore's investor day signals transparency and strategic growth plans, which can enhance investor confidence and potentially influence stock performance.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Lifecore Biomedical CEO Paul Josephs will speak at the Stephens Annual Investment Conference from November 19-21, 2024, in Nashville, Tennessee.
Why It Matters - Lifecore's CEO speaking at a prominent investment conference may boost visibility and investor confidence, potentially impacting stock performance and attracting new investment interest.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Lifecore Biomedical (NASDAQ: LFCR) will host a virtual investor day on November 21, 2024, from 8:00-9:30 a.m. ET to discuss business strategies and growth plans.
Why It Matters - Lifecore Biomedical's virtual investor day will provide insights into its growth strategy, potentially influencing stock performance and investor sentiment.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A new hire with extensive experience in pharmaceutical manufacturing and finance aims to enhance performance and productivity within the company.
Why It Matters - Strong leadership in pharmaceutical operations and finance can enhance company performance, potentially leading to increased profitability and stock value, attracting investor interest.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
